Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 17, 2025

HER2/ErbB2 (D8F12) XP Rabbit mAb

RRID:AB_10557104
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 4290, RRID:AB_10557104)

Antibody Information

URL: http://antibodyregistry.org/AB_10557104

Proper Citation: (Cell Signaling Technology Cat# 4290, RRID:AB_10557104)

Target Antigen: HER2/ErbB2 (D8F12) XP Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IHC-P. Consolidation on 11/2018: AB_10557104, AB_10828932. Info: Used By NYUIHC-1085.
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: HER2/ErbB2 (D8F12) XP Rabbit mAb

Description: This monoclonal targets HER2/ErbB2 (D8F12) XP Rabbit mAb

Target Organism: rat, h, m, mouse, r, human

Antibody ID: AB_10557104

Vendor: Cell Signaling Technology

Catalog Number: 4290

Record Creation Time: 20231110T064638+0000

Record Last Update: 20241115T053116+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for HER2/ErbB2 (D8F12) XP Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Treekitkarnmongkol W, et al. (2024) Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer. British journal of cancer, 131(1), 171.

Trenker R, et al. (2024) Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation. eLife, 12.

Zwirner S, et al. (2024) First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187(7), 1666.

Huang P, et al. (2024) Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK. Cell host & microbe, 32(8), 1365.

Marrocco I, et al. (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell reports. Medicine, 4(8), 101142.

McKernan CM, et al. (2022) ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. Cell reports, 40(9), 111268.

Whiteaker JR, et al. (2021) Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Cell reports

methods, 1(3).

Al-Zeheimi N, et al. (2020) Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype. British journal of pharmacology, 177(9), 2024.

Sun HL, et al. (2020) Stabilization of ERK-Phosphorylated METTL3 by USP5 Increases m6A Methylation. Molecular cell, 80(4), 633.

Lukey MJ, et al. (2019) Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer. Cell reports, 29(1), 76.

Vaseva AV, et al. (2018) KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer cell, 34(5), 807.

Freed DM, et al. (2017) EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics. Cell, 171(3), 683.